Catalyst Biosciences is a research and clinical development biopharmaceutical company focused on disorders of the complement and coagulation systems. Co.'s main product candidate is marzeptacog alfa (activated), a subcutaneously (SQ) Factor VIIa that is entering a registrational trial in patients with Hemophilia A or B with inhibitors. Co.'s complement portfolio is led by the development candidates CB 4332, which is an improved complement factor I (CFI) intended for lifelong prophylactic SQ administration in individuals with CFI deficiency; and CB 2782-PEG, a potential class C3 degrader product candidate in preclinical development for the treatment of dry age-related macular degeneration. The CBIO stock yearly return is shown above.
The yearly return on the CBIO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CBIO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|